Acadian Asset Management’s Harpoon Therapeutics, Inc. Common Stock HARP Stock Holding History

Acadian Asset Management’s Portfolio HARP Stock Details HARP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-7,670	Closed	-$29K	–	1877
2023 Q3	$29K	Sell	7,670 -1	-0%	-$7	﹤0.01%	1487
2023 Q2	$53K	Sell	7,671 -3,699	-33%	-$25.6K	﹤0.01%	1524
2023 Q1	$84K	Sell	11,370 -1,325	-10%	-$11.1K	﹤0.01%	1431
2022 Q4	$91K	Buy	12,695 +7,031	+124%	+$59.2K	﹤0.01%	1459
2022 Q3	$54K	Hold	5,664	–	–	﹤0.01%	1490
2022 Q2	$109K	Buy	+5,664	New	+$147K	﹤0.01%	1339
2021 Q3	–	Sell	-2,293	Closed	-$318K	–	2097
2021 Q2	$318K	Sell	2,293 -2,614	-53%	-$499K	﹤0.01%	1297
2021 Q1	$1.03M	Buy	4,907 +1,310	+36%	+$263K	﹤0.01%	944
2020 Q4	$598K	Buy	3,597 +1,627	+83%	+$251K	﹤0.01%	1171
2020 Q3	$334K	Sell	1,970 -290	-13%	-$41.8K	﹤0.01%	1265
2020 Q2	$375K	Buy	2,260 +1,479	+189%	+$231K	﹤0.01%	1292
2020 Q1	$90K	Buy	+781	New	+$110K	﹤0.01%	1371

Other funds holding HARP

CAM

Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

NLVP

New Leaf Venture Partners New York $43M AUM 25.55% 1-Year Est. Return

Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

SCM

Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return

Blackstone Inc New York $25.6B AUM 26.83% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Acadian Asset Management's HARP Position: Q4 2023 in Review

Acadian Asset Management sold out of Harpoon Therapeutics, Inc. Common Stock (HARP) in Q4 2023, closing a stake of 7,670 shares — an estimated $29K sold.

Acadian Asset Management first reported a position in HARP in Q1 2020 and held it in 12 quarters. The position peaked at $1.03M in Q1 2021. 41 funds tracked by Wall St. Rank hold HARP as of Q4 2023.

Acadian Asset Management reported no remaining Harpoon Therapeutics, Inc. Common Stock position as of Q4 2023 after selling out during the quarter.
Acadian Asset Management sold 7,670 Harpoon Therapeutics, Inc. Common Stock shares in Q4 2023, an estimated $29K.
Acadian Asset Management first reported a position in Harpoon Therapeutics, Inc. Common Stock in Q1 2020 and held it in 12 quarters.
Acadian Asset Management's Harpoon Therapeutics, Inc. Common Stock position peaked at $1.03M in Q1 2021.
41 funds tracked by Wall St. Rank held Harpoon Therapeutics, Inc. Common Stock as of Q4 2023.

Based on Acadian Asset Management's 13F filing for Q4 2023, filed 13 Feb 2024.